Sonoma Pharmaceuticals (NASDAQ: SNOA) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it compare to its competitors? We will compare Sonoma Pharmaceuticals to related businesses based on the strength of its risk, profitability, valuation, dividends, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Sonoma Pharmaceuticals and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sonoma Pharmaceuticals 0 0 1 0 3.00
Sonoma Pharmaceuticals Competitors 192 912 1687 67 2.57

Sonoma Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 87.62%. As a group, “Biopharmaceuticals” companies have a potential upside of 5.93%. Given Sonoma Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Sonoma Pharmaceuticals is more favorable than its competitors.

Valuation and Earnings

This table compares Sonoma Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Sonoma Pharmaceuticals $14.02 million -$12.55 million 2.68
Sonoma Pharmaceuticals Competitors $579.33 million $241.73 million -6.47

Sonoma Pharmaceuticals’ competitors have higher revenue and earnings than Sonoma Pharmaceuticals. Sonoma Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Sonoma Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals’ competitors have a beta of 1.24, indicating that their average share price is 24% more volatile than the S&P 500.

Institutional & Insider Ownership

9.8% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 44.6% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 13.3% of Sonoma Pharmaceuticals shares are held by company insiders. Comparatively, 14.0% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Sonoma Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sonoma Pharmaceuticals 54.36% -44.24% -36.04%
Sonoma Pharmaceuticals Competitors -13,098.25% 298.25% -20.03%

Summary

Sonoma Pharmaceuticals competitors beat Sonoma Pharmaceuticals on 7 of the 12 factors compared.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.

Receive News & Stock Ratings for Sonoma Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.